European Companies Search Engine

EU funding (€9,994,359): A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology Hor 3 Jun 2020 EU Research and Innovation programme "Horizon"

Overview

Text

A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology

The goal of EuCanImage is to build a highly secure, federated and large-scale European cancer imaging platform, with capabilities that will greatly enhance the potential of artificial intelligence (AI) in oncology. Firstly, the EuCanImage platform will be populated with a completely new data resource totaling over 25,000 single subjects, which will allow to investigate unmet clinical needs like never before, such as for the detection of small liver lesions and metastases of colorectal cancer, or for estimating molecular subtypes of breast tumours and pathological complete response. Secondly, the cancer imaging platform, built by leveraging the well-established Euro-Bioimaging infrastructure, will be cross-linked to biological and health repositories through the European Genome-phenome Archive, allowing to develop multi-scale AI solutions that integrate organ-level, molecular and other clinical predictors into dense patient-specific cancer fingerprints. To deliver this platform, the consortium will build upon several key European initiatives in data sharing for personalised medicine research, including EUCANCAn (cancer genomics and health data sharing), euCanSHare (cardiac imaging and omics data sharing) and EUCAN-Connect (federated data analytics). Furthermore, to foster international cooperation and leverage existing success stories, the consortium comprises the coordinators of The Cancer Imaging Archive (TCIA), the US cancer imaging repository funded by the National Cancer Institute. This will allow EuCanImage to leverage a unique 10-year long experience in cancer imaging storage, anonymisation, curation and management. Finally, a close collaboration between world renown clinical, radiomics, AI and legal experts within the consortium and beyond will establish well-needed guidelines for AI development and validation named FUTURE, for delivering Fair, Universal, Traceable, Usable, Robust and Explainable decision support systems for future cancer care.


Funded Companies:

Company name Funding amount
Barcelona Supercomputing Center Centro Nacional de Supercomputacion €351,250
Biobanks AND Biomolecular Resources Research Infrastructure Consortium (Bbmri-Eric) €310,425
Collective Minds Radiology AB €401,250
Eibir Gemeinnutzige GmbH ZUR Forderung DER Erforschung DER Biomedizinischen Bildgebung €273,125
Erasmus Universitair Medisch Centrum Rotterdam €931,563
European Association for Cancer Research €164,658
European Society OF Oncologic Imaging - Esoi Europaische Gesellschaftfur Onkologische Bildebung €18,727.93
Fundacio Centre de Regulacio Genomica €476,500
Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer €467,500
Gdanski Uniwersytet Medyczny €339,625
Hospital Clinic de Barcelona €0.00
Lietuvos Sveikatos Mokslu Universiteto Ligonine Kauno Klinikos €181,188
Lynkeus €679,500
Oncoradiomics €472,500
Siemens Healthcare GmbH €292,372
Siemens Healthineers AG €184,832
TMF - Technologie UND Methodenplattform FUR DIE Vernetzte Medizinische Forschung e. V. €0.00
Umea Universitet €526,250
Universidad del Pais Vasco/ Euskal Herriko Unibertsitatea €187,500
Universita Di Pisa €481,250
Universitat de Barcelona €1,639,991
Universiteit Maastricht €808,875
University of Arkansas €805,479

Source: https://cordis.europa.eu/project/id/952103

The filing refers to a past date, and does not necessarily reflect the current state.